Cullen/Frost Bankers’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.9M Buy
267,264
+2,635
+1% +$213K 0.21% 96
2026
Q1
$22.9M Buy
264,629
+3,988
+2% +$382K 0.26% 83
2025
Q4
$25M Sell
260,641
-4,754
-2% -$462K 0.28% 75
2025
Q3
$25.3M Sell
265,395
-11,506
-4% -$1.06M 0.29% 71
2025
Q2
$24.1M Sell
276,901
-7,360
-3% -$624K 0.3% 77
2025
Q1
$25.5M Buy
284,261
+6,604
+2% +$591K 0.36% 69
2024
Q4
$22.2M Sell
277,657
-3,054
-1% -$264K 0.3% 81
2024
Q3
$25.3M Buy
280,711
+4,447
+2% +$374K 0.34% 70
2024
Q2
$21.7M Sell
276,264
-2,859
-1% -$234K 0.31% 76
2024
Q1
$24.3M Sell
279,123
-5,574
-2% -$476K 0.36% 72
2023
Q4
$23.5M Sell
284,697
-5,219
-2% -$398K 0.37% 71
2023
Q3
$22.7M Buy
289,916
+7,258
+3% +$608K 0.4% 65
2023
Q2
$24.9M Buy
282,658
+3,277
+1% +$282K 0.42% 65
2023
Q1
$22.5M Sell
279,381
-2,429
-0.9% -$198K 0.41% 69
2022
Q4
$21.9M Buy
281,810
+30,494
+12% +$2.47M 0.42% 70
2022
Q3
$20.3M Buy
251,316
+6,305
+3% +$567K 0.46% 56
2022
Q2
$22M Buy
245,011
+4,945
+2% +$501K 0.49% 55
2022
Q1
$26.7M Buy
240,066
+1,966
+0.8% +$208K 0.52% 49
2021
Q4
$24.7M Sell
238,100
-5,554
-2% -$643K 0.47% 57
2021
Q3
$30.6M Buy
243,654
+1,518
+0.6% +$196K 0.62% 40
2021
Q2
$30.1M Buy
242,136
+4,104
+2% +$515K 0.6% 41
2021
Q1
$28.1M Buy
238,032
+15,789
+7% +$1.85M 0.62% 42
2020
Q4
$26.1M Sell
222,243
-2,997
-1% -$330K 0.6% 42
2020
Q3
$23.4M Sell
225,240
-2,968
-1% -$298K 0.58% 43
2020
Q2
$20.9M Buy
228,208
+5,302
+2% +$508K 0.55% 46
2020
Q1
$20.1M Buy
222,906
+534
+0.2% +$56.8K 0.7% 35
2019
Q4
$25.2M Sell
222,372
-15,943
-7% -$1.75M 0.69% 41
2019
Q3
$25.9M Sell
238,315
-8,861
-4% -$925K 0.77% 36
2019
Q2
$24.1M Sell
247,176
-1,698
-0.7% -$155K 0.74% 36
2019
Q1
$22.6M Buy
248,874
+32,553
+15% +$2.91M 0.69% 41
2018
Q4
$19.7M Sell
216,321
-1,007
-0.5% -$94.1K 0.73% 38
2018
Q3
$21.4M Sell
217,328
-29,816
-12% -$2.76M 0.67% 48
2018
Q2
$21.2M Sell
247,144
-22,142
-8% -$1.85M 0.66% 50
2018
Q1
$21.6M Buy
269,286
+12,674
+5% +$1.05M 0.64% 55
2017
Q4
$20.7M Buy
256,612
+2,071
+0.8% +$166K 0.66% 54
2017
Q3
$19.8M Buy
254,541
+1,177
+0.5% +$97.7K 0.65% 56
2017
Q2
$22.5M Sell
253,364
-17,502
-6% -$1.48M 0.76% 42
2017
Q1
$21.8M Buy
270,866
+18,323
+7% +$1.43M 0.74% 42
2016
Q4
$18M Sell
252,543
-8,037
-3% -$631K 0.62% 63
2016
Q3
$22.5M Sell
260,580
-18,898
-7% -$1.65M 0.81% 32
2016
Q2
$24.3M Buy
279,478
+15,348
+6% +$1.24M 0.9% 24
2016
Q1
$19.8M Buy
264,130
+8,092
+3% +$609K 0.74% 50
2015
Q4
$19.7M Buy
256,038
+14,948
+6% +$1.13M 0.74% 47
2015
Q3
$16.1M Buy
241,090
+28,232
+13% +$2.08M 0.64% 55
2015
Q2
$15.8M Buy
212,858
+49,388
+30% +$3.77M 0.59% 55
2015
Q1
$12.7M Buy
163,470
+121,077
+286% +$9.18M 0.48% 71
2014
Q4
$3.06M Buy
42,393
+1,428
+3% +$99.2K 0.12% 165
2014
Q3
$2.54M Sell
40,965
-77
-0.2% -$4.9K 0.1% 175
2014
Q2
$2.62M Sell
41,042
-1,388
-3% -$84.3K 0.11% 172
2014
Q1
$2.61M Sell
42,430
-208
-0.5% -$12.1K 0.11% 173
2013
Q4
$2.45M Sell
42,638
-931
-2% -$52.8K 0.11% 173
2013
Q3
$2.32M Sell
43,569
-11,570
-21% -$623K 0.11% 173
2013
Q2
$2.84M Buy
+55,139
New +$2.73M 0.15% 163

Other funds holding MDT

Cullen/Frost Bankers's MDT Position: Q2 2026 in Review

Cullen/Frost Bankers increased its Medtronic (MDT) stake by 1% in Q2 2026, buying an estimated $213K and bringing the position to 267,264 shares worth $20.9M. The position accounts for 0.21% of the portfolio, ranked #96.

Cullen/Frost Bankers first reported a position in MDT in Q2 2013 and has held it in 53 quarters since. The position peaked at $30.6M in Q3 2021. 2,128 funds tracked by Wall St. Rank hold MDT as of Q2 2026.

  • Cullen/Frost Bankers held 267,264 shares of Medtronic worth $20.9M as of Q2 2026.
  • Cullen/Frost Bankers bought 2,635 Medtronic shares in Q2 2026, an estimated $213K.
  • Medtronic made up 0.21% of Cullen/Frost Bankers's portfolio in Q2 2026, its #96 holding.
  • Cullen/Frost Bankers first reported a position in Medtronic in Q2 2013 and has held it in 53 quarters since.
  • Cullen/Frost Bankers's Medtronic position peaked at $30.6M in Q3 2021.
  • 2,128 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.